舒洛地特治疗2型糖尿病肾病尿微量白蛋白的疗效观察  

Effect of sulodexide on microalbuminuria of the third stage of type 2 diabetic nephropathy

作　　者：任健[1] 苏颉[2] 黄灿[1] 田晨光[1] 

机构地区：[1]郑州大学第二附属医院内分泌及代谢病科,450014 [2]河南省洛阳市中心医院内分泌科

出　　处：《中国现代医药杂志》2010年第11期31-33,共3页Modern Medicine Journal of China

摘　　要：目的探讨舒洛地特治疗2型糖尿病肾病尿微量白蛋白的疗效。方法 41例糖尿病肾病微量白蛋白尿期患者(200μg/min≤UAER<200μg/min)被随机分为两组,A组(18例)为常规治疗,B组(23例)为常规+舒洛地特(600LSU,iv,qd)治疗,疗程均为4周。结果治疗4周后,B组UAER降低(41.7±0.4)%明显高于A组(5.1±0.2)%。B组治疗前后以及两组治疗后UAER比较,均有统计学差异(P<0.001)。而A组治疗前后无统计学差异(P>0.05)。结论常规治疗基础上加用舒洛地特4周治疗可有效降低2型糖尿病肾病微量白蛋白尿期患者尿微量白蛋白。Objective To investigate the effect of sulodexide on the diabetic nephropathy patients with microalbuminuria.Methods 41 patients of type 2 diabetic nephropathy patients with microalbuminuria（200μg/min≤UAER200μg/min）were divided into two group according to the different treatment protocols：the group A,the regular therapy（18 patients） and the group B,the additional sulodexide（600LSU iv qd） based on regular therapy（23 patients）.The course of treatment were 4 weeks.Results UAER decreased by（5.1±0.2）% and（41.7±0.4）% in the group A and the group B respectively.Obviously,the latter had a significantly advantage in the decrease of microalbuminuria.Significant difference was noted in the UAER level of the B group compared with its pretherapy and the posttreatment of group A（P〈0.001）.But there was no significant difference between the pretherapy and the posttreatment of A group（P〉0.05）.Conclusion Four weeks therapy of additional sulodexide based on regular therapy could effectively decreased microalbuminuria in patient with type 2 diabetic nephropathy.

关 键 词：舒洛地特 2型糖尿病 糖尿病肾病 尿微量白蛋白排泄率 

分 类 号：R587.2[医药卫生—内分泌]